UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab …
2024年9月23日 · The approval of bimekizumab-bkzx for adult patients with active PsA is supported by data from the Phase 3 BE OPTIMAL and BE COMPLETE studies, in which …
UCB receives U.S. FDA approval for BIMZELX [®] (bimekizumab …
2024年11月20日 · Approval is supported by data from the two Phase 3 studies, BE HEARD I and BE HEARD II, in which bimekizumab-bkzx improved the signs and symptoms of disease vs. …
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults …
2023年10月18日 · BIMZELX ® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate-to-severe plaque psoriasis
FDA Approves Bimekizumab for Hidradenitis Suppurativa
2024年11月20日 · The US Food and Drug Administration has approved bimekizumab, a humanized interleukin (IL)-17A and IL-17F antagonist, for the treatment of adults with …
BE HEARD Trials Highlight Efficacy of Bimekizumab in …
2 天之前 · On November 20, the FDA approved bimekizumab (Bimzelx; UCB Pharma) for use in patients with moderate to severe hidradenitis suppurativa. News. All News Press Releases …
Jeff Stark, MD: Insights on the Approval of Bimekizumab for HS
2 天之前 · Jeff Stark, MD, a rheumatologist and head of Medical Immunology at UCB, shared insights with Dermatology Times on the recent approval of bimekizumab (Bimzelx) for treating …
UCB Announces Positive Phase 3 Studies for Bimekizumab in …
2022年12月9日 · Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines …
Bimekizumab Maintains Efficacy for PsA Up to 2 Years Among …
3 天之前 · Bimekizumab treatment of psoriatic arthritis (PsA) demonstrated robust maintenance of response at the 2-year mark, new findings suggest, and specifically among those who …
UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab …
2024年9月23日 · BIMZELX ® (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of …
UCB Announces First Detailed Data from Two Phase 3 Bimekizumab …
2022年5月23日 · Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines …